Business
Easton Pharmaceuticals Signs MOU Towards Distributing a Line of Injectable Approved Cancer Drugs for Mexico and Other Latin American Countries; Further Announces It Is Not Canceling Its Canadian Medical Marijuana Option With MDRM, Stays Committed To Medic
Easton Pharmaceuticals Signs MOU Towards Distributing a Line of Injectable Approved Cancer Drugs for Mexico and Other Latin American Countries; Further Announces It Is Not Canceling Its Canadian Medical Marijuana Option With MDRM, Stays Committed To Medic.
About this update from Easton Pharmaceuticals Inc
[{"type":"text","content":"\n \n \n Easton Pharmaceuticals Signs MOU Towards Distributing a Line of Injectable Approved Cancer Drugs for Mexico and Other Latin American Countries; Further Announces It Is Not Canceling Its Canadian Medical Marijuana Option With MDRM, Stays Committed To Medical Marijuana Industry\n \n \nEaston Pharmaceuticals Signs MOU Towards Distributing a Line of Injectable Approved Cancer Drugs for Mexico and Other Latin American Countries; Further Announces It Is Not Canceling Its Canadian Medical Marijuana Option With MDRM, Stays Committed To Medical Marijuana Industry\n \n TORONTO, ON--(Marketwired - Jun 8, 2015) - Easton Pharmaceuticals Inc. (OTC PINK: EAPH) announces it has signed an MOU agreement towards finalizing negotiations with BMV Medica S.A. de C.V. to jointly distribute and sell a line of the most common and used cancer drugs throughout Mexico and most of Latin America. The majority of these sales will be to the Mexican and other national governments through their national tender program. As a member of the North American Free Trade Agreement, Canadian-manufactured pharmaceuticals qualify for the national tender program, providing a major advantage over other manufacturers. Easton Pharmaceuticals also announces it has made the decision not to cancel its option with MDRM Canada, and stays committed to Canada's Medical Marijuana industry and Aero Farms prior to Canada's federal election in the fall of 2015.\n Easton's current joint venture partner, BMV Medical S.A. de C.V., has secured the rights for all of Mexico and other Latin American countries towards the first two of an extensive line of cancer drugs from an industry leading, world recognized Canadian Manufacturer whose name will be disclosed on closing. The cancer drugs are \"paclitaxel\" and \"docetaxel\". The manufacturer already has approval and is currently selling \"paclitaxel\" in Canada and other countries around the world, has filed regulatory documents and is well into the process of obtaining regulatory approval with Health Canada to obtaining marketing authorization for \"docetaxel\". Both of these cancer drugs are generic drugs and are amongst the most commonly prescribed for several of the most common cancers including breast, lung and ovarian cancers. In addition docetaxel is extremely difficult to manufacture with only a limited number of companies worl...